Pembrolizumab and nivolumab, drugs targeting the PD-1/PD-L1 pathway (Gaikwad et al. 2022), have been developed and are currently undergoing clinical trials for cervical cancer treatment. This evidence concerns the gene CD274 and cervical carcinoma.